What Does the Data Actually Say About the Response Rate of Ketamine for Depression?
Clinical data indicates that ketamine therapy and esketamine (Spravato) offer a 53% to 70% response rate for individuals who have not found relief with traditional antidepressants.
In clinical trials, esketamine (Spravato)—FDA-approved for adults with treatment-resistant depression and major depression with suicidal thoughts—alongside evidence-based off-label ketamine therapy, demonstrate response rates between 53% and 70% for treatment-resistant depression, which is substantially higher than traditional antidepressants at comparable stages of illness. But "response" is not binary, and it rarely looks the same from one person to the next. Understanding the published numbers, the timelines, and the clinical reality behind them is essential for anyone evaluating whether this treatment may be appropriate.
If you've spent time reading forums or message boards, you've likely encountered wildly different accounts: someone's partner felt different within hours, while another person felt nothing after three sessions. Both experiences are real. Neither is unusual. And understanding why requires looking beyond the headline statistics into how response actually unfolds across a course of treatment.
The Numbers That Matter: Ketamine Efficacy in Pivotal Trials
The most rigorous evidence for esketamine comes from two landmark clinical trial programs. The data they produced is worth examining carefully – not as abstract percentages, but as a frame for what treatment may realistically offer.
TRANSFORM-2: The Treatment-Resistant Depression Trial
The TRANSFORM-2 trial enrolled adults whose depression had not responded to at least two adequate courses of antidepressant treatment – the clinical definition of treatment-resistant depression. Participants received esketamine (Spravato) nasal spray plus a newly initiated oral antidepressant, compared against placebo nasal spray plus a newly initiated oral antidepressant.
The results demonstrated a statistically significant and clinically meaningful reduction in depression severity at four weeks. What made this finding particularly striking was the speed: most of the separation from placebo was visible within 24 hours of the first dose. For people who have waited weeks or months for a traditional antidepressant to take effect – often without meaningful improvement – that timeline represents something fundamentally different.
ASPIRE: Depression with Suicidal Ideation
The ASPIRE trials examined esketamine in a more acute population: adults with major depressive disorder and active suicidal ideation or behavior. This is the patient group for whom urgency is not theoretical – it is immediate.
In these trials, esketamine (Spravato) plus comprehensive standard of care showed rapid and significant reductions in depressive symptoms at 24 hours compared to placebo plus standard of care. The response rate in this population was notable not just for its magnitude but for its speed – providing measurable relief within a window that traditional medications simply cannot match.
The Broader Dataset for Racemic Ketamine
For off-label ketamine therapy – the racemic mixture containing both S-ketamine and R-ketamine – a systematic review and meta-analysis comparing racemic ketamine to esketamine found that both formulations demonstrated significant antidepressant effects. The ketamine response rate across studies typically falls in the 60–70% range for treatment-resistant populations, with some analyses reporting even higher numbers when looking at broader response criteria.
To put these figures in context: after a person did not respond to a third antidepressant, the likelihood of achieving remission with yet another traditional medication drops to approximately 14%. The statistic most commonly cited – that 86% of patients do not achieve remission with their third oral antidepressant – represents the clinical backdrop against which ketamine's efficacy data should be read. These are not patients who "haven't tried hard enough." These are patients for whom the standard pharmacological toolkit has been exhausted.
"When the person doesn't feel better, that challenges the patient. And sometimes you can't challenge depression – it'll challenge you right back. That's when you need to break the cycle with something different."
— Dr. Ben Yudkoff, Chief Medical Officer, Lumin Health
Response Is Not Remission: A Distinction That Changes Everything
In clinical research, "response" and "remission" are measured with specific, validated scales – most commonly the Montgomery-Åsberg Depression Rating Scale (MADRS) or the Hamilton Depression Rating Scale (HAM-D). And the distinction between the two terms is not academic. It directly shapes what patients should expect.
- Response is defined as a 50% or greater reduction in depression severity scores from baseline. It means your symptoms have been cut in half – a meaningful and often noticeable change in daily functioning.
- Remission means your scores have dropped to a level that no longer meets the threshold for clinical depression. It is closer to what most people think of when they imagine "getting better."
When published data reports a ketamine success rate of, say, 65%, that figure typically refers to response – not remission. Remission rates are generally lower, often in the 30–40% range depending on the study, the population, and the measurement timepoint. This is not a failure of the treatment. It reflects the depth and complexity of treatment-resistant depression itself.
A response without full remission still means something profound in clinical terms. It can mean the difference between being unable to get out of bed and being able to engage with your day. It can mean the first moment in months or years where the weight lifts enough to allow genuine engagement with the people and activities that matter to you. Many patients describe the shift not as "feeling happy" but as feeling capable again – as though the paralyzing certainty that nothing could change has loosened its grip.
The Four Response Trajectories: Why Your Timeline Is Not Someone Else's
One of the most important clinical frameworks we use at Lumin Health comes from Dr. Ben Yudkoff's characterization of four distinct response trajectories. This framework directly addresses the confusion that arises when patients compare their experience to others' accounts online.
1. Immediate Response
Some patients experience a perceptible shift within hours of their first session. This is the trajectory that generates the most dramatic online testimonials – and it is real. But it is not the most common pattern, and expecting it sets an unrealistic benchmark for the majority of patients. The neurobiological basis for rapid response likely involves acute glutamate modulation and the temporary quieting of what's known as the Default Mode Network – the brain system responsible for self-referential thinking. In depression, this network tends to become rigid and overactive, trapping people in cycles of rumination and negative self-perception. Ketamine's ability to temporarily modulate that pattern can produce an almost immediate sense of cognitive spaciousness.
2. Early Response (2–3 Weeks)
This is the most commonly observed trajectory for esketamine (Spravato) in clinical settings. It aligns with the typical induction phase – twice-weekly sessions over the first four weeks. The cumulative effect of repeated sessions appears to build neuroplastic change, with each session reinforcing the brain's capacity to form new synaptic connections through the release of Brain-Derived Neurotrophic Factor (BDNF). Patients in this trajectory may not notice dramatic shifts after any single session, but over two to three weeks, they begin to recognize subtle changes: sleep improves, irritability softens, engagement with daily life returns incrementally.
3. Late Response
A smaller but significant subset of patients does not show measurable improvement until later in the treatment course – sometimes six, eight, or even ten sessions in. This group is particularly vulnerable to premature discontinuation. If a patient stops after three sessions because "it's not working," they may never reach the threshold at which their particular neurochemistry begins to shift. Late response does not indicate a lesser quality of improvement – it simply reflects the reality that brains stuck in deeply entrenched depressive patterns may require more time to rewire.
4. Non-Response
Not everyone responds to ketamine treatment. Published non-response rates vary, but roughly 30–40% of treatment-resistant patients may not achieve a clinical response even with an adequate trial. This is an honest and important part of the conversation. Non-response does not mean the patient did something wrong or that their depression is "too severe." It may reflect differences in receptor biology, co-occurring conditions, concurrent medications, or factors we do not yet fully understand.
A recent analysis on personalized approaches to ketamine and esketamine for treatment-resistant depression emphasizes that identifying predictors of response – and tailoring treatment accordingly – is an active and evolving area of research.
Addressing the Forum Posts: "I Didn't Respond After One Session"
This is perhaps the most important section for anyone reading patient accounts online and trying to calibrate their expectations.
The minimum adequate trial for ketamine for depression is not one session. It is not two. For esketamine (Spravato), the induction series consists of eight sessions over four weeks, administered twice weekly. For intramuscular (IM) ketamine, the standard initial course is typically six sessions over two to three weeks. Evaluating whether the treatment "works" before completing an induction series is like stopping an antibiotic after two days and concluding it didn't help the infection.
There are specific neurobiological reasons for this. Each session builds on the last. The acute effects – glutamate release, Default Mode Network quieting, BDNF release – create conditions for synaptic growth. But synaptic growth takes time. The neuroplasticity window that ketamine opens does not close after a single session; it is a cumulative process in which the brain's capacity for new patterns strengthens with repetition.
"There's this very large cohort where something just became an automatic part of their process and they realized it happened. They didn't wake up one morning completely free of symptoms – the change snuck up on them, quietly and steadily."
— Dr. Ben Yudkoff, Chief Medical Officer, Lumin Health
If you're three sessions into an induction and feel discouraged, that is a signal to talk with your treatment team – not a signal to stop. Your clinicians can assess whether dose adjustments, medication interactions, or behavioral factors might be influencing your trajectory. At Lumin Health, this kind of ongoing clinical dialogue is foundational to how we approach ketamine's neuroplastic potential.
Why Ketamine's Efficacy Data Looks Different from Antidepressant Trials
It is worth pausing to appreciate an important methodological distinction. When we say that ketamine for treatment-resistant depression has a response rate of 60–70%, we are talking about a population that has already not responded to multiple prior treatments. These patients have, by definition, not responded to at least two adequate antidepressant courses – and often many more.
Traditional antidepressant trials, by contrast, typically enroll patients who may be medication-naïve or early in their treatment history. The response rates reported for SSRIs, SNRIs, and other monoamine-targeting medications – serotonin, norepinephrine, and dopamine – are derived from populations that are, on average, less treatment-resistant.
This means that ketamine's response rates are achieved in a harder-to-treat population, which makes them even more clinically significant. The response rate in TRANSFORM-2, the five-year post-approval data, and the growing real-world evidence base all point in the same direction: this is a treatment that works for a substantial proportion of people whom existing treatments have not served.
What Happens After Response: The Maintenance Question
Achieving a response is a meaningful milestone. Sustaining it requires a different conversation entirely.
The SUSTAIN-1 trial for esketamine (Spravato) demonstrated that patients who continued treatment were significantly less likely to relapse than those who discontinued. This finding has shaped current clinical practice: after induction, most patients transition to a maintenance phase – sessions spaced to once weekly or once every two weeks – that preserves the neuroplastic gains achieved during the initial treatment course.
For IM ketamine therapy, maintenance protocols are more variable and often individualized. Some patients find that monthly sessions are sufficient; others require more frequent treatment to sustain their response. The clinical team's role is to collaborate with you to find the schedule that supports durable improvement while minimizing treatment burden.
What matters most during this phase is not just the medication. It is what you do with the neuroplasticity window each session opens. Whether that involves psychotherapy with an outside provider, your own self-guided practice, physical activity, or intentional behavioral change – the 48–72 hours following a session represent a period of heightened capacity for new learning and pattern formation. Patients who actively engage during this window tend to report more sustained benefit over time.
How Lumin Health Approaches Response Monitoring
At Lumin Health – a psychiatrist-led practice based in the Boston Metro area and expanding to other states – response is not measured by a single data point. It is tracked across multiple dimensions: standardized depression scales, patient-reported outcomes, functional status, sleep quality, and the patient's own subjective sense of change.
This matters because some of the most meaningful shifts are not captured by a rating scale alone. A patient might not meet the statistical threshold for "response" but report that they cooked a meal for the first time in months, or called a friend they had been avoiding. These functional markers are clinically real and deeply relevant to whether treatment is helping.
Our providers – academically-affiliated and specifically trained in ketamine and esketamine – approach response monitoring as an ongoing conversation, not a pass/fail test. If a patient is not responding as expected, the clinical discussion turns to potential contributing factors: medication interactions, sleep patterns, substance use, dose optimization, or whether a different treatment modality might be more appropriate.
Frequently Asked Questions
What is the typical ketamine remission rate for treatment-resistant depression?
Ketamine remission rates in treatment-resistant populations generally range from 30–40%, depending on the study and measurement timepoint. This is notably higher than remission rates for traditional antidepressants at comparable stages where traditional medications did not provide relief, where the likelihood of remission can drop below 15%.
How many ketamine sessions do I need before I can tell if it's working?
The minimum adequate trial is the full induction series – typically six sessions for IM ketamine or eight sessions for esketamine (Spravato) over four weeks. Some patients respond earlier, but evaluating efficacy before completing the induction course may lead to premature conclusions about whether the treatment is effective for you.
Is the esketamine (Spravato) response rate different from IM ketamine?
Meta-analyses comparing racemic ketamine to esketamine have found broadly similar efficacy, though head-to-head trials are limited. The esketamine (Spravato) response rate in pivotal trials was demonstrated in rigorously controlled conditions, and real-world data continues to refine our understanding of comparative effectiveness.
What does "non-response" mean, and is it my fault?
Non-response means that the treatment did not produce a sufficient reduction in depression severity. It is not a reflection of effort, willpower, or the severity of your depression. It may reflect individual differences in neurochemistry, concurrent medications, or factors that are still being studied. If you do not respond to one modality, other options remain available.
Can ketamine therapy help if I haven't found relief with many antidepressants already?
This is precisely the population for which ketamine treatment has the strongest evidence base. Because ketamine acts on the glutamate system – entirely distinct from the serotonin, norepinephrine, and dopamine pathways targeted by traditional antidepressants – the number of prior medications that did not provide relief does not predict a poor response. The clinical data suggests that ketamine's mechanism of action may be effective regardless of how many prior treatments have not worked.
Where the Conversation Goes from Here
Numbers matter. But so does context. A ketamine success rate of 60–70% in a treatment-resistant population is a statistic worth understanding – and it is also worth understanding that behind every percentage point are individuals whose trajectories looked different from one another. Some felt relief within hours. Others needed weeks. Some did not respond at all, and found their path forward through a different door.
If you are weighing whether ketamine therapy or esketamine (Spravato) may be appropriate for you, the most important next step is not reading one more study or one more forum post. It is having a conversation with a clinical team that can evaluate your specific history, your medication profile, and your goals – and give you an honest assessment of what the data suggests for someone in your situation.
Lumin Health's team is available for that conversation. We would be grateful to walk with you toward clarity – whether that leads to treatment with us, a referral elsewhere, or simply the reassurance that comes from understanding your options more fully. You can learn more about insurance coverage and accessibility or reach out to explore whether this may be a fit.
Take the first step today.
If you or a loved one in Massachusetts and the greater Washington DC/Maryland area is struggling with depression or anxiety, Lumin Health's team of experts is ready to help. Book a free 20-minute consultation to learn if ketamine therapy could be the breakthrough you've been looking for.
Available in Massachusetts and the greater Washington DC/Maryland area.
.svg)
